• Pila Pharma dosed the first two participants in PP-CT04, a 12-week mid-stage obesity trial of oral drug candidate XEN-D0501.
• No results have been presented; safety and tolerability findings are expected later as the study progresses.
• The trial aims to show whether higher, gradually increased dosing can be used over a longer treatment period in obese patients.
• Part 2 is planned to start only if an internal safety review supports continuation following initial monitoring in Part 1.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pila Pharma AB published the original content used to generate this news brief on October 12, 2026, and is solely responsible for the information contained therein.